AFTER NMOSD ATTACKS

she may never be the same

See Why

NMOSD, Neuromyelitis Optica Spectrum Disorder.

eye
41%

of NMOSD patients were expected to be legally blind in at least 1 eye at 5 years after disease onset1*

of NMOSD patients were expected to be legally blind in at least 1 eye at 5 years after disease onset1*

LEARN ABOUT THE EARLY SIGNS

*From a retrospective study of 140 aquaporin-4 immunoglobulin G positive (AQP4-IgG+) NMOSD patients identified from Mayo Clinic records from 2005 to 2011; data based on Kaplan-Meier analysis of time to blindness in either eye.1

handicapped
22%

would require a walker at 5 years after disease onset1*

would require a walker at 5 years after disease onset1*

DISCOVER A DIAGNOSTIC PATH

*From a retrospective study of 140 AQP4-IgG+ NMOSD patients identified from Mayo Clinic records from 2005 to 2011; data based on Kaplan-Meier analysis of time to reach Expanded Disability Status Scale (EDSS) 6.1

hospital
22% to 54%

required hospital admission within 1 year of a patient’s index date2*

required hospital admission within 1 year of a patient’s index date2*

SEE THE FULL IMPACT

*Based on a retrospective study of neuromyelitis optica (NMO) patients (N=1349, of whom 134 had highly active NMO with ≥2 relapses in 12 months) that evaluated healthcare use within 12 months of a patient’s first NMO encounter (index date) in a US administrative claims database. In the non-NMO control group (N=670), 4.0% had an inpatient hospital admission.2

scroll
Crack

IN NMOSD, EVERY ATTACK MATTERS

Sign up for additional information on Neuromyelitis Optica Spectrum Disorder (NMOSD) and to receive future updates on NMOSD.

This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.

By providing my information above, I am giving Alexion and companies working with Alexion permission to contact me by mail, email, telephone, or text message for communications or marketing purposes to provide me with information about Alexion’s products, services, and programs or other topics of interest; conduct market research; or ask me about my experience with or thoughts about such topics. Alexion will not sell or transfer my information to any unrelated third party for marketing purposes without my express permission. Please see Privacy Notice.

Thank you for submitting your information

There was an error processing your request.

References: 1. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-1204. 2. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96-103.

IN NMOSD, EVERY ATTACK MATTERS

Sign up for additional information on Neuromyelitis Optica Spectrum Disorder (NMOSD) and to receive future updates on NMOSD.

This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.

By providing my information above, I am giving Alexion and companies working with Alexion permission to contact me by mail, email, telephone, or text message for communications or marketing purposes to provide me with information about Alexion’s products, services, and programs or other topics of interest; conduct market research; or ask me about my experience with or thoughts about such topics. Alexion will not sell or transfer my information to any unrelated third party for marketing purposes without my express permission. Please see Privacy Notice.

Thank you for submitting your information

There was an error processing your request.